by Elec23 | Oct 23, 2025 | News&events
We are proud to be part of Clover Biopharmaceuticals’ important achievement in advancing innovative respiratory combination vaccines. VisMederi contributed to the RSV+hMPV±PIV3 Combination Vaccines Phase I study by performing serological analyses, supporting the...
by Elec23 | Oct 22, 2025 | News&events
VisMederi continues to strengthen its engagement in metapneumovirus control and vaccine research, confirming its active role in the international scientific community. At the 10th ESWI Influenza Conference, held in Valencia from 20 to 23 October 2025, Maria Giovanna...
by Elec23 | Oct 16, 2025 | News&events
VisMederi’s Cell Mediated Immunity (CMI) Team members, Ilaria Razzano and Ilaria Ferrigno, traveled to Sofia to deliver a training session at Hera Medical Center. The focus of the training was on PBMC (Peripheral Blood Mononuclear Cells) isolation from clinical...
by Elec23 | Jun 3, 2025 | News&events
As part of the Florence Health Institute program, the VisMederi Foundation, that’s part of the VisMederi Group, greeted a group of Kent State University students in the Toscana Life Sciences Foundation auditorium on June 3rd. This yearly meeting has become a...
by Elec23 | Apr 11, 2025 | News&events
We are proud to announce that VisMederi has once again been included in the Financial Times FT 1000 ranking, placing 483rd among Europe’s fastest-growing companies in 2025. The eighth annual list, compiled in collaboration with Statista, recognises companies that have...
